ClarityMD Proven to Clear Acne Fast Without Irritating Skin - Applied Clinical Trials

ADVERTISEMENT

See our 2013 Buyers Guide Digital Edition.
ClarityMD Proven to Clear Acne Fast Without Irritating Skin New Journal of Drugs In Dermatology Published Study Shows ClarityMD To Be Highly Effective In Treating Inflammatory And Non-Inflammatory Acne


ClarityMD Proven to Clear Acne Fast Without Irritating Skin

New Journal of Drugs In Dermatology Published Study Shows ClarityMD To Be Highly Effective In Treating Inflammatory And Non-Inflammatory Acne

PR Newswire

WESTLAKE VILLAGE, Calif., June 11, 2014 /PRNewswire/ -- Envy Medical, Inc., a leader in professional skincare products and services, is excited to announce the publication of a new study in the June issue of the Journal of Drugs in Dermatology (JDD) proving the superior efficacy of its highly innovative acne system – ClarityMD . Designed by Envy Medical, Inc., the clinical study proves that ClarityMD is effective in quickly and gently clearing both inflammatory and non-inflammatory acne within days.

Already known for its blemish blasting speed, ClarityMD works up to three times faster than leading acne products. The easy two-step system combines the potent combination of salicylic acid, bakuchiol, and bisabolol in a Deep Pore Cleanser and Clarifying Gel to treat acne in two simple steps.  It also contains anti-aging ingredients and exfoliants such as Glycolic acid to help skin to look and feel better immediately and increase radiance over time.

Conducted by an independent group of researchers, the study results indicate clearance of acne lesions at an unprecedented pace. On average, 59% of acne in subjects was cleared in the first seven days, with 91.6% acne eradication achieved in 14 days. Participants' skin had virtually complete acne clearance of 98.5% over the six-week study.

In addition to its remarkably fast-acting formulation, ClarityMD marks a significant innovation for acne sufferers because it eliminates the irritation generally associated with treating the affliction. Most acne studies involving prescription or over-the-counter (OTC) acne products show that these tend to over-dry skin and increase redness and irritation over the course of treatment.

"The biggest hurdle in the treatment of acne is patient non-compliance due to intolerance and irritation cause by many acne medications," said Felipe Jimenez, Ph.D., Envy Medical's Chief Scientific Officer. "This study is significant because it proves that acne medications don't need to be harsh to be effective. Results demonstrated that ClarityMD clears acne with unprecedented speed and that any redness or irritation the study volunteers were experiencing from their acne prior to starting the study dissipated within the first 14 days."

ClarityMD is also one of the few products to also show a significant positive effect on non-inflammatory acne (blackheads/whiteheads), showing over 56% reduction over the six-week period.

According to Ashish C. Bhatia, M.D., FAAD, the lead author of the study and Medical Director for Dermatologic Research at the DuPage Medical Group in Naperville, IL., "This all adds up to a highly effective new tool for treating acne, that also meets the demands of adult acne sufferers who want a skincare regimen that will clear and prevent acne while actually improving the tone and texture of skin."

ABOUT ENVY MEDICAL

Envy Medical develops, markets and sells highly effective non-invasive skin rejuvenation therapies for patients suffering from either dermatologic or aesthetic conditions. The Company's lead products include SilkPeel®, a breakthrough device combining exfoliation with Dermalinfusion® for deeper tissue delivery of active ingredients and better patient outcomes. Envy is also the exclusive global licensor of skin brightening peptides including Lumixyl®, developed at Stanford University. The Lumixyl peptide is now also available as a topical solution for SilkPeel procedures, addressing hyperpigmentation and photo-damage. More information can be found at www.envymedical.com.

SOURCE Envy Medical, Inc.

ADVERTISEMENT

blog comments powered by Disqus

ADVERTISEMENT

UPCOMING CONFERENCES

8th Annual Forum on Transparency and Aggregate Spend 2014
Washington, DC
August 18-20, 2014

eSource Data in Clinical Investigations
Philadelphia, PA
August 20-21, 2014

Pharmacovigilance 2014
Philadelphia, PA
September 10-11, 2014

Collaborative Research Summit
Philadelphia, PA
October 15-16, 2014

See All Conferences >>

Survey
As it creates a plan to implement the US biosimilar pathway, should FDA:
Borrow heavily from EMA's pathway program?
Borrow lightly from EMA's pathway program?
Create entirely its own pathway program?
Borrow heavily from EMA's pathway program?
86%
Borrow lightly from EMA's pathway program?
7%
Create entirely its own pathway program?
7%
View Results
Untitled Document

Click here